 |
|
|
| |
EFFICACY AND SAFETY OF THE INTERFERON-FREE COMBINATION OF FALDAPREVIR (BI 201335) + BI 207127 ± RIBAVIRIN IN TREATMENT-NAIVE PATIENTS WITH HCV GT-1 AND COMPENSATED LIVER CIRRHOSIS: RESULTS FROM THE SOUND-C2 STUDY
|
| |
| |
Reported by Jules Levin
AASLD Nov 9-13 2012 Boston
Vicente Soriano1, Ed Gane2, Peter Angus3, Felix Stickel4, Jean-Pierre Bronowicki5, Stuart Roberts6, Michael Manns7, Stefan Zeuzem8, Richard Vinisko9, Ivona Herichova10, Wulf Bocher11, Jerry Stern9, and Federico Mensa9
Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain; 2. Auckland Clinical Studies, Auckland, New Zealand; 3. Austin Health, Liver Transplant Unit, Heidelberg, Australia; 4. Universitatsklinik fur Viszerale Chirurgie und Medizin, Bern, Switzerland; 5. Hopital de Brabois, Vandoeuvre, France; 6. Alfred Hospital, Dept Gastroenterology, Melbourne, Australia; 7. Medizinische Hochschule Hannover, Hannover, Germany; 8. Klinikum der J. W. Goethe-Universitat, Frankfurt am Main, Germany; 9. Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT, USA; 10. Boehringer Ingelheim Pharma RCV GmbH & Co KG, Vienna, Austria;
11. Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, Germany
|
| |
|
|
|
|
|
